The headline beat is misleading due to non-recurring items. Monitor the Q3 2026 earnings for organic revenue growth in diagnostics and pharmaceuticals, and track cash burn rate. The raised full-year guidance provides a positive narrative, but the underlying business trends remain weak.
Drug in focus
OPK drug pipeline →OPK-8801001
● Neutral Named in this 8-K- Impact
- Phase
- Phase 1/2a
- Time to market
- At least 5-7 years, assuming successful completion of Phase 1/2a, Phase 2, and Phase 3 trials followed by regulatory filing and review.
- Next catalyst
- None dated
What to watchOPK-8801001 just began Phase 1/2a dosing on October 27, 2026, so the next meaningful catalyst is initial safety and pharmacodynamic data, likely not for 12+ months. For OPKO Health, the bigger near-term drivers are the Labcorp/BioReference asset sale closing and NGENLA royalty revenue trends. This early-stage program is unlikely to move the stock in the foreseeable future.
How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jul 28 $1.65entry
- T+1 · 4mo ago −17.27%α −15.73% · $1.37
- T+5 · 4mo ago −20.61%α −22.88% · $1.31
- T+20 · 3mo ago −9.70%α −13.08% · $1.49
- T+60 · 27d ago −3.03%α −7.38% · $1.60
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
OPKO Health reported Q2 2026 revenue of $163.5M, above the $131.2M consensus estimate, and a net loss of $0.01 per share, significantly beating the consensus estimate of -$0.11. The beat was driven by a $29.4M non-cash revenue recognition from shares received in the Nicoya agreement amendment and a $18.1M earnout from the Labcorp asset sale, masking ongoing weakness in core diagnostics revenue, which fell to $74.5M from $101.1M a year ago. Full-year revenue guidance was raised to $560M-$585M from the prior $530M-$560M range, but the company remains unprofitable with an operating loss of $7.0M, and the quality of the beat is low due to its reliance on non-recurring items.
Key Financial Metrics
Key Facts
- Q2 2026 total revenue of $163.5M vs $156.8M YoY, beating consensus of $131.2M.
- Net loss of $0.01 per share vs consensus -$0.11, a 90.9% beat.
- Revenue beat driven by $29.4M non-cash revenue from Nicoya equity stake and $18.1M Labcorp earnout.
- Core diagnostics revenue declined to $74.5M from $101.1M YoY, impacted by the Labcorp asset sale.
- Full-year 2026 revenue guidance raised to $560M-$585M from prior $530M-$560M.
- Cash burn continues: cash & equivalents fell to $300.8M from $369.1M at year-end 2025.
- Operating loss improved to $7.0M from $60.0M YoY, but still negative.
Financial Impact
Revenue beat of $32.3M vs consensus, but $29.4M of that is non-cash from a licensing amendment. Core operations remain loss-making.
Risk Factors
- Core diagnostics revenue continues to decline post-Labcorp sale.
- Cash burn of ~$68M in H1 2026 reduces financial flexibility.
- Dependence on non-recurring items (Nicoya, Labcorp earnout) for revenue growth is unsustainable.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-318069 |
| Document: opk-20260727.htm | 0001193125-26-318069 |
| Document: 0001193125-26-318069-index-headers.html | 0001193125-26-318069 |
| Document: 0001193125-26-318069-index.html | 0001193125-26-318069 |
| Document: 0001193125-26-318069.txt | 0001193125-26-318069 |
| 8-K Data (Synthetic) | 0001193125-26-318069 |
Track record
10 reports on OPK
The track record builds as more bullish or bearish reports settle.
Filters
- Nov 4, 202612d ago 8-K Neutral 6/10 Entry $1.75 Now $1.62 −7.43% settles Dec 4
- Nov 4, 202612d ago Press Release Neutral 6/10 No price data
- Oct 15, 20264w ago 8-K Bullish 7/10 Entry $1.53 to $1.68 Now $1.62 +5.88% ▲ +9.80% +10.97% vs SPY
- Jul 27, 202616w ago 8-K Mixed 5/10 Viewing Entry $1.65 to $1.49 Now $1.62 −1.82% ▼ −9.70% −13.08% vs SPY
- Jul 23, 202616w ago Press Release Neutral 1/10 Entry $1.17 to $1.46 Now $1.62 +38.46% ▲ +24.79% +21.48% vs SPY
- Jun 15, 202622w ago Press Release Neutral 3/10 Entry $1.40 to $1.23 Now $1.62 +15.71% ▼ −12.14% −11.39% vs SPY
- May 15, 202626w ago DEFA14A Neutral 4/10 Entry $1.13 to $1.39 Now $1.62 +43.36% ▲ +23.01% +21.43% vs SPY
- Apr 30, 202628w ago Press Release Neutral 4/10 Entry $1.13 to $1.43 Now $1.62 +43.36% ▲ +26.55% +21.58% vs SPY
- Apr 22, 202629w ago Press Release Bullish 7/10 Entry $1.23 to $1.15 Now $1.62 +31.71% ▼ −6.50% −9.67% vs SPY
- Apr 21, 202629w ago Press Release Neutral 1/10 Entry $1.23 to $1.15 Now $1.62 +31.71% ▼ −6.50% −9.67% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers